ArticleJournal of osteoporosis2026

Cardiovascular Outcomes Following Therapeutic Sclerostin Inhibition Compared With Alternative Anabolic Therapies: A Real-World Propensity Score-Matched Analysis.

Maxim John Levy Barnett et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.